Soria A, et al. - In adults with moderate-to-severe atopic dermatitis (AD), researchers tested the safety and effectiveness of dupilumab, a humanized monoclonal antibody targeting the α subunit of the interleukin (IL)-4 and IL-13 receptors. In the dupilumab groups compared with the placebo groups in pivotal studies, injection site reactions, nasopharyngitis, conjunctivitis, and transient increases in eosinophil counts from baseline were higher. A recent study identified new regional dermatoses in 17 AD patients treated with dupilumab, with 14 cases involving the facial area, while in a post hoc analysis of data derived from 4 phase 3 clinical trials, there was an equivalent improvement of AD with dupilumab in different anatomical regions.